Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Novo Nordisk A/S purchases B shares worth DKK 954 million from Novo Holdings A/S under the 2018 share repurchase programme

Novo Nordisk A/S
Posted on: 05 Feb 18

Bagsværd, Denmark, 5 February 2018 - Novo Nordisk A/S has today entered into an agreement to purchase 3,087,410 B shares (nominal DKK 0.20) of a value of DKK 954 million from Novo Holdings A/S. This transaction is part of Novo Nordisk's 2018 share repurchase programme of up to a total of DKK 14.0 billion to be executed during a 12 months period beginning 1 February 2018. The transaction price is DKK 308.90 per share and has been calculated as the volume weighted average market price from 1 February to 5 February 2018 in the open window following the announcement of Novo Nordisk A/S' 2017 financial results.

Prior to the sale of B shares, Novo Holdings A/S' ownership of Novo Nordisk A/S was 28.1% of the share capital and 75.5% of the votes. Following the transaction, Novo Holdings A/S owns 107,487,200 A shares (nominal DKK 0.20) and 32,145,318 B shares (nominal DKK 0.20), corresponding to 27.9% of the capital and 75.4% of the votes in Novo Nordisk A/S.

The transaction is in line with the announcement on 1 February 2018 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S share capital around 28%.

Transactions related to Novo Nordisk's incentive programmes have resulted in a net transfer from Novo Nordisk of 495,918 B shares in the period from 1 February 2018 to 5 February 2018. Novo Nordisk A/S owns a total of 63,102,269 B shares of DKK 0.20, corresponding to 2.5% of the share capital, as treasury shares including this transaction. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.

Further information

Novo Holdings Communication    
Christian Mostrup Scheel+45 3067 4805 cims@novo.dk
     
Novo Nordisk Media:    
Katrine Sperling+45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US)+1 609 786 8316 kiau@novonordisk.com
     
Novo Nordisk Investors :    
Peter Hugreffe Ankersen+45 3075 9085 phak@novonordisk.com
Hanna Ögren+45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen+45 3079 4461 armk@novonordisk.com
Christina Kjær+45 3079 3009 cnje@novonordisk.com
Kasper Veje (US)+1 609 235 8567 kpvj@novonordisk.com

Company announcement No 9 / 2017 

PR180205_NHAS_buyback.UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire
HUG#2166259
GlobeNewswire
globenewswire.com

Last updated on: 06/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.